Specifically, Bean et al. evaluated 701 bone or soft tissue sarcomas by immunohistochemistry analysis for ASS1 expression and found that most primary bone tumors (87.2%, 34/39) and soft tissue tumors (86.4%, 572/662) had low ASS1 expression. This evidence concerns the gene ASS1 and soft tissue sarcoma.